EYET Eyetech Pharmaceuticals (MM)

Eyetech to Announce First Quarter 2005 Financial Results on April 20, 2005 NEW YORK, April 7 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET), today announced that it plans to report first quarter 2005 financial results on Wednesday, April 20, 2005 after the U.S. financial markets close. (Logo: http://www.newscom.com/cgi-bin/prnh/20050407/EYETLOGO ) Eyetech's senior management will hold a conference call and webcast to discuss the results and provide a company update on Thursday, April 21, 2005 at 8:30 a.m. Eastern Time, before the U.S. financial markets open. Live audio of the conference call will be available to investors, members of the news media and the general public by dialing 888-275-0218 (in the United States) or 706-679-7756 (internationally). A playback of the call will be available through May 5, 2005 by dialing 800-642-1687, passcode 5170755 (in the United States) or 706-645-9291, passcode 5170755 (internationally). To access the call by live webcast, please log on to the Investor Relations section of our corporate website at http://www.eyetech.com/. An archived version of the webcast will be available at the same location through May 5, 2005. About Eyetech Pharmaceuticals, Inc. Eyetech Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye. Eyetech's initial focus is on diseases affecting the back of the eye. Eyetech is commercializing and further developing Macugen(R) (pegaptanib sodium injection) with Pfizer Inc for the treatment of neovascular AMD. Macugen is also being studied for other indications including diabetic macular edema and retinal vein occlusion. http://www.newscom.com/cgi-bin/prnh/20050407/EYETLOGODATASOURCE: Eyetech Pharmaceuticals, Inc. CONTACT: Glenn Sblendorio, Chief Financial Officer of Eyetech Pharmaceuticals, Inc., +1-212-824-3100, fax, +1-212 824 3240, Web site: http://www.eyetech.com/

Copyright